September 4, 2024 3-5PM ET
Wednesday on The Robert Scott Bell Show:
Glimpse into the Future of Food The future of food is being reshaped by corporate monopolies, government regulations, and new technological advances in food production. Industrial agriculture, reliant onchemical fertilizers, pesticides, and subsidies, has led to soil depletion and nutrient-deficient foods. The consolidation of food companies has allowed large corporations to dominate the market, while small farmers face increasing challenges, often being pushed out. New trends, such as plant-based meats, lab-grown proteins, and insect-based foods, are being promoted by governments and organizations like the World Economic Forum, under the guise of combating climate change. However, these foods raise concerns about their nutritional value, potential long-term health effects, and ethical issues related to the centralization of food production. There is growing skepticism about whether these innovations can truly improve public health or if they serve corporate interests. The article argues that decentralizing food production and supporting small farmers and homesteaders is essential to maintaining a healthier and more sustainable food supply. It warns against the risks of relying on factory-produced, synthetic foods, advocating instead for real food grown naturally and locally.
Special Guest Erin Saxton
In her roles as CEO of CUE Productions and Chief Content Officer of CUE Broadcast, Erin Saxton is a visionary leader at the forefront of media innovation. She orchestrates the creation of groundbreaking narratives that captivate audiences worldwide, leveraging nearly two decades of experience in the industry. With a knack for asking the right questions and uncovering the heart of any story, Erin has conducted thousands of interviews with guests and clients, honing her skills as a powerhouse producer and protégé of Barbara Walters.
Throughout her illustrious career, Erin has earned multiple Emmy nominations for her contributions to nationally syndicated television shows such as the Barbara Walters Specials, The Rosie O’Donnell Show, Good Morning America, and The View. Building on this foundation, she has carved a niche for herself in consulting, specializing in executing effective PR and marketing campaigns.
Following her tenure at The View, Erin ventured into entrepreneurship, founding her own marketing agency where she led national media strategies for notable figures like Jack Canfield, contributing to the sale of over 500 million books. Her expertise spans both B2B and B2C markets, and she is actively involved in associations and events, delivering keynote addresses as an expert in her field to audiences across the country.
After years of launching her clients’ books, Erin is penning her own, entitled CHASING PRETTY: THE DAY THE FAT LADY STOPPED SINGING, which is anticipated to release in the near future.
Erin drives innovation and strategic growth. At CUE Broadcast, she oversees the creation of impactful programming that resonates with diverse audiences. As CEO of CUE Productions, her leadership has propelled the company to new heights, expanding its influence in the industry. Erin’s blend of creative vision and business acumen continues to elevate CUE’s brand and solidify her as a dynamic force in media.
Welcome to another episode of “Homeopathic Hits” on The Robert Scott Bell Show.
Today, we’re spotlighting Eryngium Aquaticum, a homeopathic remedy known for its effectiveness in treating urinary disorders, prostate health issues, and gout.
Eryngium Aquaticum offers a natural and comprehensive approach to managing these conditions, providing relief from discomfort and supporting overall urinary and metabolic health.
Download the Information Sheet
Hour 2
New Trend Of Pharma Selling Directly To Consumers Raises Questions Pharmaceutical companies like Eli Lilly and Pfizer are launching direct-to-consumer platforms, such as LillyDirect and PfizerForAll, that allow patients to bypass traditional healthcare intermediaries. These platforms enable patients to connect with telehealth providers, receive prescriptions, and have medications delivered to their homes. While these initiatives offer greater convenience and access to treatments, they raise concerns about potential conflicts of interest. Critics argue that these programs could undermine the doctor-patient relationship, particularly when telehealth providers—who may lack comprehensive knowledge of a patient’s medical history—prescribe medications directly. For example, LillyDirect offers discounts on low-dose versions of Zepbound, a weight-loss drug, only through its platform, steering patients toward its products. The American College of Physicians has voiced concerns about the role of telehealth in these direct sales efforts, emphasizing the need for responsible care in collaboration with established healthcare providers. These platforms, while simplifying access to medications and services, present ethical dilemmas and questions about the extent to which pharmaceutical companies might influence patient care and prescription decisions.
T
here Are No Licensed COVID Vaccines for Kids Under 12 — But CDC Wants Babies to Get 3 Pfizer Shots by Age 9 Months The CDC’s updated guidancerecommends that babies as young as 6 months old receive three doses of Pfizer’s COVID-19 vaccine by the time they are 9 months old, despite the fact that there are no licensed COVID vaccines for children under 12. Both Pfizer and Moderna vaccines have been granted only Emergency Use Authorization (EUA) for this age group. Critics, including Children’s Health Defense CEO Mary Holland, argue that these recommendations are misguided, especially given concerns about the safety and effectiveness of the earlier COVID shots. VAERS data shows thousands of reported deaths following COVID-19 vaccination, with 187 deaths reported in children and teens. The CDC has been accused of misleading the public by asserting the vaccines are “safe,” when EUA products are only required to meet the standard of “may be effective.” The CDC’s approach, which continues to push unlicensed vaccines for young children, has sparked criticism for prioritizing pharmaceutical interests over public safety and for failing to provide adequate transparency about the risks.
Fentanyl vaccine heads for clinical trials, with goal of saving lives Researchers at the University of Houston are preparing to begin clinical trials for a fentanyl vaccine aimed at combating the opioid crisis. The vaccine, which has shown promise in animal studies, is designed to prevent fentanyl from entering the brain and causing an overdose. Biopharmaceutical startup Ovax, which acquired the license to produce the vaccine, plans to start Phase I trials in 2025. These trials will focus on safety, side effects, and dosage in people with a history of opioid use disorder, a challenging population to recruit. While some critics argue that resources should be allocated to existing treatments like methadone and buprenorphine, proponents see the vaccine as a complementary tool in the fight against opioid addiction. The development of opioid vaccines, which has been in progress since the 1970s, relies on adjuvants to stimulate the immune system. Although it may take years before a vaccine becomes widely available, researchers are optimistic that this innovative solution could save lives and improve existing treatments for opioid addiction.
Alzheimer’s-like brain changes found in long COVID patients New research from the University of Kentucky’s Sanders-Brown Center on Aging suggests thatlong COVID patients may experience cognitive impairments similar to those seen in Alzheimer’s disease. The study, published in Alzheimer’s & Dementia, found that COVID-19 survivors with “brain fog” show abnormalities in brain activity, neuroinflammation, and astrocyte activation, which resemble early-stage Alzheimer’s and related dementias. These findings highlight the possibility that both conditions share common biological mechanisms. The research emphasizes the need for regular brain function monitoring in long COVID patients, using tools like electroencephalography (EEG), to detect early signs of cognitive decline. Damage to astrocytes, key brain support cells, is believed to cause the abnormal brain activity seen in both conditions. This discovery could lead to new treatment strategies and earlier interventions to prevent further cognitive deterioration in long COVID patients. As the study continues, researchers are particularly focused on how EEG monitoring can predict long-term outcomes and evaluate the effectiveness of treatments to prevent cognitive decline.
Childhood HIV vaccination strategy shows promise in study Research from Weill Cornell Medicine shows promise for a new childhood HIV vaccination strategy that could offer protection before the risk of contracting HIV increases in adolescence. The study, published in Science Immunology, used a series of six vaccinations in young nonhuman primates, designed to stimulate an immune response that could potentially lead to lifelong protection. The vaccine targets the protein on the surface of HIV particles, aiming to produce broadly neutralizing antibodies that prevent the virus from entering and infecting CD4 T cells. The researchers found that the immune systems of infants and children tend to mount more effective responses to the virus than adults. The modified vaccine successfully produced precursor antibodies in three of the five primates, though further research is needed to generate a fully mature immune response. The study represents an important step toward developing an HIV vaccine that could be given early in life, alongside routine childhood vaccines, to prevent future infections.
Questions of The Day
Hi Guys,
1. Do you agree with your guest about Candida?-he said to stay away from certain vitamins, I believe he also said to be careful as to how much copper one uses.
2. Does taking the “Balance Oil” take the place of eating fish?
3. What herb or natural substance is helpful for toe fungus
Bill
Remember Friends, The Power to Heal is Yours!
